Parth Rao, MD

Articles by Parth Rao, MD

Attacking a Moving Target: Understanding Resistance and Managing Progression in EGFR-Positive Lung Cancer Patients Treated With Tyrosine Kinase Inhibitors

ByBenjamin P. Levy, MD,Parth Rao, MD,Daniel J. Becker, MD,Kevin Becker, MD

July 16th 2016

In this article, we review the available literature addressing the competing treatment strategies in EGFR-Positive Lung Cancer and attempt to clarify best treatment practices, including the emerging role of T790M-directed therapies.

Latest Updated Articles

Attacking a Moving Target: Understanding Resistance and Managing Progression in EGFR-Positive Lung Cancer Patients Treated With Tyrosine Kinase Inhibitors
July 16th 2016

Parth Rao, MD

Articles by Parth Rao, MD

Attacking a Moving Target: Understanding Resistance and Managing Progression in EGFR-Positive Lung Cancer Patients Treated With Tyrosine Kinase Inhibitors

Latest Updated Articles

Trending on CancerNetwork

FDA Approves OncoMate MSI Dx as Pembrolizumab Companion Diagnostic in MSI-H Solid Tumors

FDA Approves Pimicotinib for Tenosynovial Giant Cell Tumors

Hyperthermic Mitomycin C Yields 68% 1-Year HG-RFS in BCG-Unresponsive NMIBC

European Commission Expands Melflufen Label to Third-Line Multiple Myeloma

Acylfulvene Prodrug LP-184 Shows Tolerability in Recurrent Glioblastoma